Gavin Setzen, MD
Otolaryngology · Albany, NYNPI 1063419232
Payments from drug & device makers
Across 365 payments — averaging $819.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Stryker$196K
- Aerin Medical Inc.$70K
- Smith+Nephew$14K
- Neurent Medical Limited$8K
- Lilly USA, LLC$4K
- Arrinex, Inc.$3K
- plus $5K from 29 others
What the payments were for
- Consulting fees$218,31090%
- Speaking & faculty fees$3,7502%
- Travel & lodging$13,4046%
- Food & beverage$7,8233%
- Education$670%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Stryker | 147 | $196,148 |
| Aerin Medical Inc. | 9 | $69,980 |
| Smith+Nephew | 14 | $13,511 |
| Neurent Medical Limited | 6 | $8,130 |
| Lilly USA, LLC | 1 | $3,750 |
| Arrinex, Inc. | 2 | $2,869 |
| Intersect ENT, Inc. | 8 | $529 |
| GSK | 18 | $425 |
| Optinose US, Inc. | 14 | $393 |
| Sanofi | 20 | $385 |
| Jazz Pharmaceuticals Inc. | 18 | $377 |
| Regeneron Healthcare Solutions, Inc. | 21 | $367 |
| Acclarent, Inc | 5 | $346 |
| CSL Behring | 12 | $221 |
| AstraZeneca | 13 | $215 |
| Harmony Biosciences LLC | 6 | $191 |
| Alk-abello, Inc | 7 | $131 |
| Pharming Healthcare, Inc. | 5 | $124 |
| Amgen | 1 | $122 |
| Novartis | 4 | $103 |
| Grifols USA, LLC | 6 | $101 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $91 |
| Kaleo, Inc. | 5 | $81 |
| Pfizer | 4 | $71 |
| Aimmune Therapeutics, Inc. | 2 | $46 |
| Medtronic | 1 | $42 |
| Greer Laboratories, Inc. | 1 | $39 |
| Johnson & Johnson | 1 | $35 |
| Shire North American Group Inc | 2 | $29 |
| Avadel CNS Pharmaceuticals, LLC | 2 | $28 |
| Axsome Therapeutics, Inc. | 1 | $26 |
| Phathom Pharmaceuticals, Inc. | 2 | $23 |
| Hikma Pharmaceuticals USA | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VIVAER STYLUS$69,927
- LATERA$53,133
- CLARIFIX CRYOTHERAPY DEVICE$51,133
- XPRESS ENT DILATION SYSTEM$40,451
- SCOPIS ENT$39,482
- ENTELLUS - XPRESS ENT DILATION SYSTEM$35,035
- ORTHOMAP$34,433
- TGS GUIDEWIRE$17,000
- SHAVER SYSTEM$16,250
- ENTELLUS MEDICAL FOCESS SINUSCOPE$15,500
- NEUROMARK Device$7,953
- NEUROMARK Radiofrequency Console$7,953
- NA$7,150
- ZEPBOUND$3,750
- XPRESS LOPROFILE$1,942
- N/A$1,630
- Cyclone$565
- TruDi Navigation System$485
- RHINAER STYLUS$462
- PROPEL$399
How this compares
$298,973 in reported general payments places this provider in the 95th percentile of 701 otolaryngology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Budesonide | 122 | $29,364 |
| Fluticasone Propionate | 434 | $10,950 |
| Ipratropium Bromide | 208 | $7,701 |
| Famotidine | 508 | $7,693 |
| Mometasone Furoate | 49 | $6,147 |
| Azelastine Hcl | 176 | $5,022 |
| Omeprazole | 379 | $4,993 |
| Epinephrine | 20 | $3,420 |
| Montelukast Sodium | 247 | $2,551 |
| Pantoprazole Sodium | 71 | $1,224 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 22 | $861 |
| Cimetidine | 11 | $787 |
| Levocetirizine Dihydrochloride | 58 | $774 |
| Lansoprazole | 19 | $648 |
| Ofloxacin | 11 | $560 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Hikma Pharmaceuticals USAEpinephrine | $16 | $3,42020 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 701 otolaryngology providers in New York.
Other otolaryngology in Albany
- Nora PerkinsAlbany$315K
- Robert KellmanSyracuse$2.5M
- Anthony DelsignoreNew York$966K
- Roheen RaithathaNew York$882K
- Dennis KrausNew York$524K
- Ashutosh KackerNew York$387K
- Lawrence LustigNew York$383K
- Brett MilesNew York$368K
- Alfred Marc IloretaNew York$342K
- Li-Xing ManRochester$253K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.